MIM
XFOR icon

Monashee Investment Management’s X4 Pharmaceuticals XFOR Stock Holding History

Monashee Investment Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14,242
Closed -$466K – 84
2023
Q3 		$466K Sell
14,242
-4,851
-25% -$212K 0.19% 69
2023
Q2 		$1.11M Buy
+19,093
New +$981K 0.27% 55
2021
Q4 		– Sell
-18,714
Closed -$2.97M – 124
2021
Q3 		$2.97M Sell
18,714
-443
-2% -$72.9K 0.55% 41
2021
Q2 		$3.74M Hold
19,157
– – 0.45% 51
2021
Q1 		$4.95M Buy
+19,157
New +$5.03M 0.76% 26
2017
Q4 		– Hold
0
– – – 79

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Monashee Investment Management's XFOR Position: Q4 2023 in Review

Monashee Investment Management sold out of X4 Pharmaceuticals (XFOR) in Q4 2023, closing a stake of 14,242 shares — an estimated $466K sold.

Monashee Investment Management first reported a position in XFOR in Q1 2021 and held it in 5 quarters. The position peaked at $4.95M in Q1 2021. 93 funds tracked by Wall St. Rank hold XFOR as of Q4 2023.

  • Monashee Investment Management reported no remaining X4 Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Monashee Investment Management sold 14,242 X4 Pharmaceuticals shares in Q4 2023, an estimated $466K.
  • Monashee Investment Management first reported a position in X4 Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • Monashee Investment Management's X4 Pharmaceuticals position peaked at $4.95M in Q1 2021.
  • 93 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2023.

Based on Monashee Investment Management's 13F filing for Q4 2023, filed 12 Feb 2024.